HDAC Inhibitors for Neurodegenerative Diseases

📖 Wiki Page

therapeutic939 wordssynced 2026-04-02

HDAC Inhibitors for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HDAC Inhibitors for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Epigenetic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Histone Deacetylases (HDACs)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Ricolinostat (ACY-1215)</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Vorinostat</td>
<td>Alzheimer's Disease</td>
</tr>
</table>

Hdac Inhibitors For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

...

HDAC Inhibitors for Neurodegenerative Diseases

Introduction

Overview

Mermaid diagram (expand to render)

Histone deacetylase (HDAC) inhibitors are a class of drugs that block the activity of histone deacetylases, enzymes that remove acetyl groups from histone proteins. By inhibiting HDACs, these agents increase histone acetylation, promoting a more open chromatin state and facilitating gene expression. In neurodegenerative diseases, [HDAC](/entities/hdac-enzymes) inhibitors have shown promise in reducing pathology and improving cognitive and motor function in preclinical models. [@inhibition2018]

Mechanism of Action

HDAC inhibitors work through several mechanisms relevant to neurodegeneration:

Epigenetic Regulation: Increased histone acetylation promotes expression of neuroprotective genes, including brain-derived neurotrophic factor (BDNF) and other neurotrophic factors.

[α-Synuclein](/proteins/alpha-synuclein) Aggregation: HDAC inhibitors, particularly HDAC6 inhibitors, can reduce α-synuclein aggregation by promoting [autophagy](/entities/autophagy) and lysosomal degradation.

[Tau](/proteins/tau) Pathology: Class I HDAC inhibitors (HDAC1, 2, 3) can reduce [tau](/proteins/tau) phosphorylation and aggregation through transcriptional regulation of tau kinases and phosphatases.

Neuroinflammation: HDAC inhibitors suppress pro-inflammatory gene expression in [microglia](/entities/microglia), reducing neuroinflammation.

Mitochondrial Function: Some HDAC inhibitors improve mitochondrial biogenesis and function in neuronal cells.

HDAC Classes and Drug Candidates

Class I HDACs (HDAC1, 2, 3, 8)

Vorinostat (SAHA): FDA-approved for cutaneous T-cell lymphoma; shown to reduce [Aβ](/proteins/amyloid-beta) toxicity in AD models
Romidepsin (FK228): Potent Class I inhibitor; preclinical studies in PD models
Valproic Acid: Used for epilepsy/bipolar disorder; has HDAC inhibitory activity; mixed clinical results in AD

Class IIa HDACs (HDAC4, 5, 7, 9)

Trichostatin A: Experimental compound; neuroprotective in HD models
Scriptaid: Experimental HDAC inhibitor; improves learning in AD models

Class IIb HDACs (HDAC6, 10)

Tubastatin A: Selective HDAC6 inhibitor; promotes α-syn and tau clearance via autophagy
ACY-1215 (Ricolinostat): HDAC6 inhibitor in clinical trials for ALS
Citarinostat (ACY-241): Selective HDAC6 inhibitor; cognitive benefits in AD models

Class III HDACs (Sirtuins)

SRT2104: SIRT1 activator; in development for neurodegeneration
SRT3025: SIRT1 activator; improves cognition in AD models

Disease-Specific Applications

Alzheimer's Disease

HDAC2 is elevated in AD brain and correlates with memory deficits
HDAC inhibitors reverse memory deficits in AD mouse models
Class I and IIa HDAC inhibitors show most promise
Current focus on selective HDAC6 inhibitors with better brain penetration

Parkinson's Disease

HDAC inhibitors protect dopaminergic [neurons](/entities/neurons) from α-syn toxicity
HDAC6 inhibitors promote clearance of Lewy body proteins
Valproic acid and vorinostat have shown neuroprotective effects

Huntington's Disease

HDAC inhibitors reduce mutant [huntingtin](/proteins/huntingtin-protein) aggregation
Improve motor function and survival in HD mouse models
Vorinostat and sodium butyrate have been studied

ALS

HDAC inhibitors may benefit SOD1 and [TDP-43](/proteins/tdp-43) models
ACY-1215 (ricolinostat) in clinical trials for ALS
Focus on HDAC6 selective inhibition to avoid Class I side effects

Clinical Trials

Adverse Effects

Common side effects include:

Fatigue, nausea, diarrhea
Thrombocytopenia (platelet decrease)
Weight loss
Class I inhibitors: more systemic toxicity
HDAC6 selective inhibitors: improved tolerability

Research Directions

[Blood-Brain Barrier](/entities/blood-brain-barrier) Penetration: Developing HDAC inhibitors with improved CNS delivery

Isoform Selectivity: Creating highly selective inhibitors to reduce off-target effects

Combination Therapy: Combining HDAC inhibitors with other therapeutic agents

Biomarker Development: Identifying biomarkers to predict treatment response

External Links

[HDAC Inhibitors - Nature Reviews Drug Discovery](https://www.nature.com/nrd/)
[Epigenetic Therapy Research - NIH](https://www.nih.gov/)
[ClinicalTrials.gov - HDAC Inhibitors](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=HDAC)
[Alzheimer's Association](https://www.alz.org/)
[Cochrane Review - HDAC Inhibitors](https://www.cochranelibrary.com/)

Background

The study of Hdac Inhibitors For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[^1] Hahnen E, et al, Neuroprotective effects of histone deacetylase inhibitors in models of Huntington's disease (2008)

[^2] Govindarajan N, et al, Reducing HDAC2 ameliorates cognitive deficits in a mouse model for Alzheimer's disease (2013)

[^3] Du G, et al, Neuroprotective effects of HDAC6 inhibitors in Parkinson's disease models (2015)

[^4] Simões-Pires C, et al, HDAC6 as a target for neurodegenerative diseases: what makes it different from other HDACs? ACS Med Chem Lett (2013)

[^5] Ionescu A, et al, SIRT1 and SIRT2 activity in aging and neurodegeneration (2020)

[^6] Chen X, et al, HDAC6 promotes α-synuclein aggregation and propagation (2020)

[^7] Shein NA, et al, Histone deacetylase inhibitors as therapeutic agents for Alzheimer's disease (2019)

[^8] Janczura KJ, et al, Inhibition of HDAC6 corrects cognitive dysfunction in experimental models of Alzheimer's disease (2018)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — 0.64 · Target: HDAC
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — 0.64 · Target: HDAC
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

HDAC Inhibitors for Neurodegenerative Diseases

HDAC Inhibitors for Neurodegenerative Diseases

Introduction

Overview

HDAC Inhibitors for Neurodegenerative Diseases

Introduction

Overview

Mechanism of Action

HDAC Classes and Drug Candidates

Class I HDACs (HDAC1, 2, 3, 8)

Class IIa HDACs (HDAC4, 5, 7, 9)

Class IIb HDACs (HDAC6, 10)

Class III HDACs (Sirtuins)

Disease-Specific Applications

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

ALS

Clinical Trials

Adverse Effects

Research Directions

See Also

External Links

Background

Allen Brain Atlas Resources

References

Related Hypotheses